Simplifying Global Compliance
Biologics Manufacturers Need More Adaptable, Modular Strategies: Tufts Study
Clinical Trials Advisor
Makers of biopharmaceuticals will need to become more modular and agile to adjust for trends in personalized medicine and oncology, according to the Tufts Center for the Study of Drug Development.
To View This Article:
Subscribe To Clinical Trials Advisor
Copyright ©2018. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing